An assessment of zonisamide as an anti-epileptic drug

Expert Opinion on Pharmacotherapy

Volumn 1, Issue 6, 2000, Pages 1245-1260

  Jain, Kewal K ^a  

^a JAIN PHARMABIOTECH   (Switzerland)

Author keywords

Anti epileptic drugs; Clinical trials; Epilepsy; Myoclonic epilepsy; Tonic clonic seizures; Zonisamide

Indexed keywords

ANTICONVULSIVE AGENT; ISOXAZOLE DERIVATIVE; ZONISAMIDE;

ADOLESCENT; ADULT; AGED; ANIMAL; CHILD; CLINICAL TRIAL; EPILEPSY; FEMALE; HUMAN; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PREGNANCY; REVIEW;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTICONVULSANTS; CHILD; CLINICAL TRIALS; EPILEPSY; FEMALE; HUMANS; ISOXAZOLES; MIDDLE AGED; PREGNANCY;

EID: 0034278612     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.1.6.1245     Document Type: Article

References (65)

1. DIALER M, JOHANNESSEN SI, KUPFERBERG HJ et al.: Progress report on new antiepilcptic drugs: a summary of the fourth EUat conference (EILAT IV). Epilepsy Res. (1999) 34:1-41. Source of information about drugs in development for epilepsy.
2. ROGAWSKI MA, LE DQ, UYAKUL D et al.: Anticonvulsant efficacy of ADO (5-aminocarbonyl-10,ll-dihydro-5Hdibenzo[a,d]cyclohepten-5,10-imine) after acute and chronic dosing in mice. Epilepsia (1995) 36:566-571.
3. SIGEL E, BAUR R, NETZER R et al.: The antiepileptic drug AWD 131-138 stimulates different recombinant isoforms of the rat GABA(A) receptor through the benzodiazepine binding site. Nctimsci. Lett. (1998) 245:85-88.
4. KOZAK A, DOLINA S, KAMBURG S et al.: DP-VPA, a novel prodrug of VPA has enhanced protective effect in genetically epilepsy-prone mice. Soc. Nenrosci. Abstr. (1997) 23(part 2):2l63.
5. MONAGHAN EP, NA YALTA LA, SHUM L et al.: Initial human experience with ganaxolone, a neuroactive steroid with antiepileptic activity. Epilepsia (1997) 38:1026-1031.
6. JONES FA, DA VIES JA: The anticonvulsant effects of the enantiomers of losigamone. Br. J. Pharmacol. (1999) 128:1223-1228.
7. BIBER A, DIENEL A: Pharmacokinetics of losigamone, a new antiepileptic drug, injiealthy male volunteers. Int.J. Clin. Phannacol. Tl)er. (1996) 34:6-11.
8. BRYANS JS, WUSTROW DJ: 3-substituted GABA analogs with central nervous system activity: a review. Med. Res. Rev. (1999) 19:149-177.
9. DAVIES JA: Remacemide hydrochloride: a novel antiepileptic agent. Gen. Pbarmacol. (1997) 28:499-502.
10. RUNDFELDT C: The new anticonvulsant retigabinc (D-23129) acts as an opener of K channels in neuronal cells. Eitr.J. Phannacol. (1997) 336:243-249-
11. BLOTNIK S, BERGMAN F, DIALER M: The disposition of valproyl glycinamidc and valproyl glycine m rats. Pbarmacol. Res. (1997) 14:873-878.
12. MAURIZISJC, MADELMONTJC, RAPP M étal: Disposition and metabolism of 2,6-dimethylbenzamidc n-(5-methyl-3-isoxazolyl) (D2916) in male and female rats. DmgMetab. Dispos. (1997) 25:33-39.
13. JAIN KK: An assessment of rufinamide as an antiepileptic in comparison with other drugs in clinical development. Exp. Opin. Invest. £>n/gs(2000) 9:829-840.
14. WALKER MC, PATSALOS PN: Clinical pharmacokinetics of new antiepileptic drugs. Pbarmacol. Tber. (1995) 67:351-384.
15. JAIN KK: Neuroprotection. Jain PharmaBiotech, Basel, Switzerland (2000). Role of anti-epileptics drugs as neuroprotectives is described.
16. ELAN PHARMA: Zonegran (zonisamide): product monograph. San Francisco, California, USA (2000).
17. NAGATOMI A, MISHIMA M, TSUZUKI O et al.: Utility of a rectal suppository containing the antiepileptic drug zonisamide. Blol. Pbarm. Bull. (1997) 20(8):892-896.
18. KITO M, MAEHARA M, WATANABE K: Mechanisms of T-type calcium channel blockade by zonisamide. Seizure (1996) 5:115-119.
19. +, carbamazcpine and zonisamide on hippocampal extracellular glutamate monitored with a microdialysis electrode. Br. J. Pbarmacol. (1998) 124:1277-1285.
20. MORI A, NODA Y, PACKER L: The anticonvulsant zonisamide scavenges free radicals. Epilepsy Res. (1998) 30:153-158.
21. MASUDA Y, KARASAWA T, SHIRAISHI Y et al.-. sulfamoylmethyl-l,2-bcnzisoxazole, a new type of anticonvulsant drug - pharmacological profile. Arzneimittelforscbiing (i960) 30:477-483.
22. ITO T, HORI M, MASUDA Y et al.: 3-sulfamoyImethyl1,2-benzisoxazole, a new type of anticonvulsant drug electroencephalographic profile. Arzneimittelforscbung (1980) 30:603-609.
23. WADA Y, HASEGAWA H, OKUDA H étal.: Anticonvulsant effects of zonisamidc and phenytoin on seizure activity of the feline visual cortex. Brain Dei'. (1990) 12:206-210.
24. SHIMIZU M, UNO H, ITO T et a!.-. Research and development of zonisamide, a new type of antiepileptic drug. Yaktigakii Zassbi (1996) 116:533-547.
25. TAKANO K, TANAKA T, FUJITA T et al.: Zonisamide: elcctrophysiological and metabolic changes in kainic acid-induced liuibic seizures in rats. Epilepsia (1995) 36:644-648.
26. MIMAKI T, SUZUKI Y, TAGAWA T et al.: Interaction of zonisamidc with bcnzodiazcpinc and GABA receptors in rat brain. Med.J. Osaka Univ. (1990) 39:13-17.
27. OKADA M, HIRANO T, KAWATA Y et al.: Biphasic effects of zonisamidc on serotonergic system in rat hippocampus. Epilepsy Res. (1999) 34:187-197.
28. OKADA M, KANEKO S, HIRANO T et al.: Effects of zonisamide on dopaminergic system. Epilepsy Res. (1995) 22:193-205.
29. HAYAKAWA T, HIGUCHI Y, NIGAMIII et al: Zonisamide reduces hypoxic-ischcmic brain damage in neonatal rats irrespective of its anticonvulsive effect. Etir. J. Pharmacol. (1994) 257:131-136.
30. MINATO H, KIKUTA C, FUJITANI B étal.: Protective effect of zonisamide, an antiepileptic drug, against transient focal cerebral ischemia with middle cerebral artery occlusion-rcpcrfusion in rats. Epilepsia (1997) 38:975-980.
31. OWEN AJ, IJAZ S, MIYASHITA H et al.: Zonisamide as a neuroprotective agent in an adult gerbil model of global forebrain ischemia: a histological, in vti'o microdialysis and behavioural study. Brain Res. (1997) 770:115-122.
32. LEPPIK, SHAH J, SHELLENBERGER K et al.: Zonsiamide phanuacökinctics: direct relationship between oral dose and blood levels. Epilepsia (1999) 40(Suppl. 2):286 ().
33. MIMAKI T: Clinical pharmacology and therapeutic drug monitoring of zonisamidc. Ther. Dnig Moult. (1998) 20:593-597. A good review of clinical pharmacology.
34. KOCHAK G.M, PAGE JG, BUCHANAN RA et al.: Steadystate pharmacokinctics of zonisamidc, an antiepileptic agent for treatment of refractory complex partial seizures./ Clin. Pharmacol. (1998) 38:166-171.
35. PERUCCA E, DIALER M: The clinical pharmacokinetics of the newer antiepileptic drugs. Focus on topiramatc, zonisamidc and tiagabine. Clin. Pharinacokinet. (1996) 31:29-46.
36. NAKASA H, NAKAMURA H, ONO S et eil.: Predicüon of drug-drug interactions of zonisamide metabolism in humans from in vitro data- Ear. J. Clin. Pharmacol. (1998) 54:177-183.
37. IEIRI I, MORIOKA T, KIM S et al.: Pharmacoklnetic study of zonisamide in patients undergoing brain surgery. J. Phann. Phannacol. (1996) 48:1270-1275.
38. SHINODA M, AKITA M, HASEGAWA M et al.: The necessity of adjusting the dosage of zonisamide when coadministercd with other anti-epileptic drugs. Biol. Pharm. Bull. (1996) 19:1090-1092. -
39. WILBUR K, ENSOM MHH: Pharmacokinctic drug interactions between oral contraceptives and secondgeneration anticonvulsants. Clin. Pbarmacokinet. (2000) 38:355-365.
40. SUZUKI N, SEKI T, YAMAWAKI H et al.: Therapy of pédiatrie epilepsy with AD-810 (zonisamide). Shonika RinsboWSl) 40:3147-3152.
41. TAGAWA T, MIMAKI T, SHUTO H et al.: Treatment of pédiatrie epilepsies with zonisamide (AD-810) efficacy and blood concentration. Shonika Shinryo (1988) 51:539-543.
42. HOSODA N, MIURA H, TAKANASHI S et al.: Once dailydose of zonisamide monotherapy in the control of partial seizures in children with cryptogcnic localization-related epilepsies: clinical effects and their pharmacological basis. Jpn. J. Psychiat. Keurol. (1994) 48:335-337.
43. ITO T, YAMAGUCHI T, MIYAZAKI H et al: Pharmacokinctic studies of AD-810, a new anticpilcptic compound. Phase I trials. Arzneimittelforscbiing (1982) 32:1581-1586.
44. WILENSKY AJ, FRIEL PN, OJEMANN LM etal: Zonisamide in epilepsy: a pilot study. Epilepsia (1985) 26:212-220.
45. SACKELLARES JC, DONOFRIO PD, WAGNERJG etal.: Pilot study of zonisamide (l,2-benzisoxazole-3methanesulfonamide) in patients with refractory partial seizures. Epilepsia (1985) 26:206-211.
46. FUKUSHIMA K, YAGI K, SEIKO M et al.: A clinical Phase U study of a new anticpileptic drug, zonisamide on the refractory epilepsy in childhood. Shonika Rinsho (1987) 40:3389-3397.
47. LEPPIK IE, \\1LLMORE LJ, HUMAN RW et al.: Efficacy and safety of zonisamide: results of a multicentcr study. Epilepsy Res. (1993) 14:165-173.
48. SCHMIDT D, JACOB R, LOISEAU P et al.: Zonisamide for add-on treatment of refractory partial epilepsy: a European double-blind trial. Epilepsy Res. (1993) 15:67-73.
49. OGUNI H, IINUMA K, SEKI T etal.: Open clinical Phase III trial of a new antiepilcptic drug zonisamide for childhood epilepsy. Jpn.J. Pediatrics (1988) 41:439-450.
50. ONO T, YAGI K, SEINO M: Clinical efficacy and safety of a new anticpilcptic drug, zonisamide. A multiinstitutional Phase III study. Seisbin Igaku (1988) 30:471-482.
51. LEPPIK I, SEINO M, YAGI K et al.-. International évaluation of zonisamidc efficacy. l\'eiiro!og)' (1998) 50:A101 ().
52. CHADWICK DW, MARSON AG: Zonisamidc for drug-resistant partial epilepsy. Cochrane Database Syst. Rev. (2000) 2:CD001416.
53. YAGI K, PRIVITERA MD: Efficacy of zonisamide monotherapy. Xeurology (2000) 54(Suppl. 3):P03.099 ().
54. KAWAWAKI H, KURIMASA H, TOMIWA K et al.: Efficacy of zonisamidc in West syndrome. Epilcpsia (1999) 40(Suppl. 2):68 ().
55. SUZUKI Y, NAGAI T, ONO J et al.: Zonisamide monotherapy in newly diagnosed infantile spasms. Epllepsia (1997) 38:1035-1038.
56. YANAI S, HANAI T, NARAZAKI O: Treatment of infantile spasms with zonisamide. Brain Dei'. (1999) 21:157-101.
57. WALLACE SJ: Myoclonus and epilepsy in childhood: a review of treatment with valproate, cthosuximide, lamotriginc and zonisamidc. Epilepsy Res. (1998) 29:147-154.
58. KYLLERMAN M, BEN-MENACHEM E: Zonisamide for progressive myoclonus epilepsy: long-term observations in seven patients. Epilepsy Res. (1998) 29:109-114.
59. KANBA S, YAGI G, KAMIJ1MA K et al.: The first open study of zonisamidc, a novel anticonvulsant, shows efficacy- in mania. Pmg. Neiiropsycbopharmacol. Bio!. Psychiatry (1994) 18:707-715.
60. PETERS DH, SORKIN EM: Zonisamide. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in epilepsy. Drugs (1993) 45:760-787.
61. SHIMIZU T, YAMASHITA Y, SATOI M et al.: Heat strokelike episode in a child caused by zonisamidc. Brain Dei'. (1997) 19:366-368.
62. WATANABE K, OKUMURA A, HAYAKAWA F et al.: Oligohidrosis caused by zonisamide. A'o To Hattatsit (1996) 28:44-47.
63. MIYAMOTO T, KOHSAKA M, KOYAMA T: Psychotic episodes during zonisamidc treatment. Seizure (2000) 9:65-70.
64. KUMAGAI N, SEKI T, YAMAWAKI H et al.: Monotherapy for childhood epilepsies with zonisamidc. Jpn. J. Psychiatry Neitrol. (1991) 45:357-359.
65. SHELLENBERGER K, BECK K: Safety of zonasimidc in Japanese children. Epilepsia (1999) 40(Suppl. 7):94 (Abstract).